FP 21399

Drug Profile

FP 21399

Latest Information Update: 14 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Lexigen; Lexigen Pharmaceuticals
  • Developer Lexigen Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 14 Jun 2006 No development reported - Phase-II for HIV infections treatment in USA (IV-infusion)
  • 06 Oct 2000 A phase I study has been added to the adverse events, pharmacokinetics and Viral infections therapeutic use sections
  • 22 Jun 1999 Fuji ImmunoPharmaceuticals is now called Lexigen Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top